Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...

The CRISPR-led gene-editing revolution is set to begin next month in its first ever trial in humans. The small phase 1 trial, to take place in China, will be investigating the method’s safety ...

It’s a new way to create “bi-paternal” mice that can survive to adulthood—but human applications are still a long way off.

CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, thanks to the FDA approval of its one-shot gene therapy Casgevy for two ...

Analysts say they see signs of malaise in China’s domestic economy, but those problems were offset mainly by robust exports and a $1 trillion trade surplus. By Keith Bradsher Reporting from ...

In a news release on Friday morning, China's National Bureau of Statistics reported its economy grew 5% in 2024 from a year ago, meeting its official target. Analysts polled by Reuters had ...

China’s president has been supplying his “dear friend” Vladimir Putin with advanced technologies and helping to prop up the Russian economy, and he is studying Russia’s ability to ...

LIKE LORD VOLDEMORT from Harry Potter, “Made in China 2025” is an initiative which induces so much fear and loathing abroad that Chinese officials dare not speak its name. The plan ...

China is committed to continuing its participation in the WHO and the Paris climate accord, expressing concern over US President Trump’s orders to withdraw from both. Beijing emphasizes the ...